K
Kerstin Göbel
Researcher at University of Münster
Publications - 60
Citations - 2527
Kerstin Göbel is an academic researcher from University of Münster. The author has contributed to research in topics: Experimental autoimmune encephalomyelitis & Multiple sclerosis. The author has an hindex of 23, co-authored 60 publications receiving 2077 citations.
Papers
More filters
Journal ArticleDOI
Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature
Christoph Kleinschnitz,Peter Kraft,Angela Dreykluft,Ina Hagedorn,Kerstin Göbel,Michael K. Schuhmann,Friederike Langhauser,Xavier Helluy,Tobias Schwarz,Stefan Bittner,Christian T. Mayer,Marc Brede,Csanad Varallyay,Mirko Pham,Martin Bendszus,Peter M. Jakob,Tim Magnus,Sven G. Meuth,Yoichiro Iwakura,Alma Zernecke,Tim Sparwasser,Bernhard Nieswandt,Guido Stoll,Heinz Wiendl +23 more
TL;DR: A novel and unexpected role of Tregs in a primary nonimmunologic disease state is defined, which reduced microvascular thrombus formation and improved cerebral reperfusion on stroke, as revealed by ultra-high-field magnetic resonance imaging at 17.6 Tesla.
Journal ArticleDOI
FTY720 Ameliorates Acute Ischemic Stroke in Mice by Reducing Thrombo-Inflammation but Not by Direct Neuroprotection
Peter Kraft,Eva Göb,Michael K. Schuhmann,Kerstin Göbel,Carsten Deppermann,Ina Thielmann,Alexander M. Herrmann,Kristina Lorenz,Marc Brede,Guido Stoll,Sven G. Meuth,Bernhard Nieswandt,Waltraud Pfeilschifter,Christoph Kleinschnitz +13 more
TL;DR: Induction of lymphocytopenia and concomitant reduction of microvascular thrombosis are key modes of FTY720 action in stroke, and findings in Rag1−/− mice and cultured neurons argue against direct neuroprotective effects of F TY720.
Journal ArticleDOI
Platelets Contribute to the Pathogenesis of Experimental Autoimmune Encephalomyelitis
Harald F. Langer,Eun-Young Choi,Eun-Young Choi,Eun-Young Choi,Hong Zhou,Rebecca Schleicher,Kyoung-Jin Chung,Kyoung-Jin Chung,Zhongshu Tang,Kerstin Göbel,Khalil Bdeir,Antonios Chatzigeorgiou,Connie H.Y. Wong,Sumeena Bhatia,Michael J. Kruhlak,John W. Rose,James Burns,Kenneth E. Hill,Hongchang Qu,Yongqing Zhang,Elin Lehrmann,Kevin G. Becker,Yunmei Wang,Daniel I. Simon,Bernhard Nieswandt,John D. Lambris,Xuri Li,Sven G. Meuth,Paul Kubes,Triantafyllos Chavakis,Triantafyllos Chavakis +30 more
TL;DR: Platelets contribute to the pathogenesis of EAE by promoting CNS inflammation by promoting platelet adhesion and inflammatory actions of platelets and targeting of GPIb&agr; attenuated EAE in mice resulted in significantly ameliorated disease development and progression.
Journal ArticleDOI
l-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients
Nicholas Schwab,Tilman Schneider-Hohendorf,Vilmos Posevitz,Johanna Breuer,Kerstin Göbel,Susanne Windhagen,Bruno Brochet,Patrick Vermersch,Christine Lebrun-Frenay,Anita Posevitz-Fejfar,Ruggero Capra,Luisa Imberti,Vera Straeten,Juergen Haas,Brigitte Wildemann,Joachim Havla,Tania Kümpfel,Ingrid Meinl,Kyle Niessen,Susan Goelz,Christoph Kleinschnitz,Clemens Warnke,Dorothea Buck,Ralf Gold,Bernd C. Kieseier,Sven G. Meuth,John Foley,Andrew T. Chan,David Brassat,Heinz Wiendl +29 more
TL;DR: The cell-based assessment of the percentage of l-selectin-expressing CD4 T cells could provide an urgently needed biomarker for individual PML risk assessment.
Journal ArticleDOI
Endothelial TWIK-related potassium channel-1 (TREK1) regulates immune-cell trafficking into the CNS
Stefan Bittner,Tobias Ruck,Michael K. Schuhmann,Michael K. Schuhmann,Alexander M. Herrmann,Hamid Moha Ou Maati,Nicole Bobak,Kerstin Göbel,Friederike Langhauser,David Stegner,Petra Ehling,Marc Borsotto,Hans-Christian Pape,Bernhard Nieswandt,Christoph Kleinschnitz,Catherine Heurteaux,Hans-Joachim Galla,Thomas Budde,Heinz Wiendl,Sven G. Meuth +19 more
TL;DR: Altered mitogen-activated protein (MAP) kinase signaling, actin remodeling and upregulation of cellular adhesion molecules as potential mechanisms of increased migration in TREK1-deficient mice suggest TREK-1 activating compounds may be used therapeutically to treat diseases related to BBB dysfunction.